[go: up one dir, main page]

MX2019014988A - Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii. - Google Patents

Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.

Info

Publication number
MX2019014988A
MX2019014988A MX2019014988A MX2019014988A MX2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A MX 2019014988 A MX2019014988 A MX 2019014988A
Authority
MX
Mexico
Prior art keywords
reducing
patients
type
diabetes mellitus
cardiovascular events
Prior art date
Application number
MX2019014988A
Other languages
English (en)
Inventor
Norman R Rosenthal
Douglas K Ways
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019014988A publication Critical patent/MX2019014988A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a métodos para reducir, prevenir o desacelerar la progresión de los factores de riesgo cardiovascular y/o la enfermedad cardiovascular, que comprende la administración de canagliflozina.
MX2019014988A 2017-06-12 2018-06-11 Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii. MX2019014988A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2019014988A true MX2019014988A (es) 2020-08-06

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014988A MX2019014988A (es) 2017-06-12 2018-06-11 Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.

Country Status (15)

Country Link
US (2) US20180353470A1 (es)
EP (1) EP3638250A1 (es)
JP (2) JP2020523408A (es)
KR (1) KR20200014406A (es)
CN (1) CN110740735A (es)
AU (1) AU2018283781B2 (es)
BR (1) BR112019026120A2 (es)
CA (1) CA3066874A1 (es)
CO (1) CO2019013940A2 (es)
EA (1) EA202090028A1 (es)
IL (1) IL271100A (es)
MX (1) MX2019014988A (es)
TW (1) TWI835735B (es)
UA (1) UA127987C2 (es)
WO (1) WO2018229630A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827184B (zh) * 2021-08-03 2023-12-21 國立政治大學 第2型糖尿病併發症的風險評估系統與方法
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100942622B1 (ko) 2003-08-01 2010-02-17 미쓰비시 타나베 파마 코퍼레이션 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
DK2385374T4 (en) * 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
KR101869110B1 (ko) * 2010-05-11 2018-06-19 미쓰비시 타나베 파마 코퍼레이션 카나글리플로진 함유 정제
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP2017504649A (ja) * 2014-01-31 2017-02-09 ヤンセン ファーマシューティカ エヌ．ベー． 腎障害及び脂肪性肝障害の治療並びに予防のための方法
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Also Published As

Publication number Publication date
EP3638250A1 (en) 2020-04-22
JP2020523408A (ja) 2020-08-06
CA3066874A1 (en) 2018-12-20
CO2019013940A2 (es) 2020-01-17
BR112019026120A2 (pt) 2020-07-07
KR20200014406A (ko) 2020-02-10
CN110740735A (zh) 2020-01-31
JP2023113644A (ja) 2023-08-16
TW201904584A (zh) 2019-02-01
WO2018229630A1 (en) 2018-12-20
UA127987C2 (uk) 2024-03-06
US20180353470A1 (en) 2018-12-13
TWI835735B (zh) 2024-03-21
AU2018283781B2 (en) 2023-09-28
IL271100A (en) 2020-01-30
EA202090028A1 (ru) 2020-04-03
AU2018283781A1 (en) 2019-12-19
US20210000792A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
MX2021002321A (es) Nuevos metodos.
MX2018011088A (es) Composicion farmaceutica que comprende empagliflozina y sus usos.
HK1220980A1 (zh) 用於治療龐貝氏症的方法和組合物
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MX2019000677A (es) Células miméticas de células b.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
EP4137147A3 (en) Uses of abaloparatide in reducing fracture risk
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
MX2019014988A (es) Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MX2016012127A (es) Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos.
BR112017015840A2 (pt) método de tratamento ou prevenção de eventos aterotrombóticos em pacientes com histórico de infarto do miocárdio
UA117243C2 (uk) Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії
WO2014187964A3 (en) Novel treatment of metabolic diseases